Abstract B272: The novel PIM kinase inhibitor SGI-1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma
Devalingam Mahalingam(The University of Texas at San Antonio Health Science Center), Steffan T. Nawrocki(University of Arizona), Ernest Medina(The University of Texas at San Antonio Health Science Center), Jennifer S. Carew(University of Arizona), Pietro Taverna, Ronan Swords(University of Miami), David J. Bearss(Unknown), Gavin Choy(SuperGen (United States)), Francis J. Giles(National University of Ireland), Kevin R. Kelly(Keck Hospital of USC)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782